The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma
Open accessAbstract
Many patients with chronic hepatitis caused by hepatitis C virus (HCV) infection develop liver fibrosis with high risk for hepatocellular carcinoma (HCC), but the mechanism underling this process is unclear. Conversely, transforming growth factor beta (TGF-β) activates not only TGF-β type I receptor (TβRI) but also c-Jun N-terminal kinase (JNK), which convert the mediator Smad3 into two distinctive phosphoisoforms: C-terminally phosphorylated Smad3 (pSmad3C) and linker-phosphorylated Smad3 (pSmad3L). Whereas the TβRI/pSmad3C pathway suppresses epithelial cell growth by upregulating p21WAF1 transcription, JNK/pSmad3L-mediated signaling promotes extracellular matrix deposition, partly, by upregulating plasminogen activator inhibitor 1 (PAI-1). We studied the domain-specific Smad3 phosphorylation in biopsy specimens representing chronic hepatitis, cirrhosis, or HCC from 100 patients chronically infected with HCV, and correlated Smad3 phosphorylation with clinical course. As HCV-infected livers progressed from chronic hepatitis through cirrhosis to HCC, hepatocytic pSmad3L/PAI-1 increased with fibrotic stage and necroinflammatory grade, and pSmad3C/p21WAF1 decreased. Of 14 patients with chronic hepatitis C with strong hepatocytic pSmad3L positivity, 8 developed HCC within 12 years; only 1 of 12 showing little pSmad3L positivity developed HCC. We further sought molecular mechanisms in vitro . JNK activation by the pro-inflammatory cytokine interleukin-1β stimulated the pSmad3L/PAI-1 pathway in facilitating hepatocytic invasion, in the meantime reducing TGF-β-dependent tumor-suppressive activity by the pSmad3C/p21WAF1 pathway. Conclusion: These results indicate that chronic inflammation associated with HCV infection shifts hepatocytic TGF-β signaling from tumor-suppression to fibrogenesis, accelerating liver fibrosis and increasing risk for HCC. (HEPATOLOGY 2007;46:48–57.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
TGF-β signalling from cell membrane to nucleus through SMAD proteins
Heldin, C.-H., Miyazono, K., & ten Dijke, P. (1997) · Nature · doi:10.1038/37284 · Cited by 3,696
Classification of chronic hepatitis: Diagnosis, grading and staging
Desmet, V. J., Gerber, M., Hoofnagle, J. H., Manns, M., & Scheuer, P. J. (1994) · Hepatology · doi:10.1002/hep.1840190629 · Cited by 2,593
TGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
Terminology of nodular hepatocellular lesions
Wanless, I. R. (1995) · Hepatology · doi:10.1002/hep.1840220341 · Cited by 1,130
TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights
Moses, H. L., Yang, E. Y., & Pietenpol, J. A. (1990) · Cell · doi:10.1016/0092-8674(90)90155-8 · Cited by 959
Poynard, T., Yuen, M.-F., Ratzin, V., & Lai, C. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15109-4 · Cited by 809
Kolb, M., Margetts, P. J., Anthony, D. C., Pitossi, F., & Gauldie, J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12568 · Cited by 753
Serum levels of cytokines in chronic liver diseases
Tilg, H., Wilmer, A., Vogel, W., Herold, M., Nölchen, B., Judmaier, G., & Huber, C. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91122-k · Cited by 739
Eitzman, D. T., McCoy, R. D., Zheng, X., Fay, W. P., Shen, T., Ginsburg, D., & Simon, R. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118396 · Cited by 558
Role of Transforming Growth Factor-beta Signaling in Cancer
de Caestecker, M. P. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.17.1388 · Cited by 522
Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications
Friedman, S. L. (2004) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0055 · Cited by 498
Blocking IL-1 in systemic inflammation
Dinarello, C. A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050640 · Cited by 494
Moustakas, A., & Kardassis, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6733 · Cited by 354
Smad3 Signaling Is Required for Epithelial-Mesenchymal Transition of Lens Epithelium after Injury
Saika, S., Kono-Saika, S., Ohnishi, Y., Sato, M., Muragaki, Y., Ooshima, A., Flanders, K. C., Yoo, J., Anzano, M., Liu, C.-Y., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63153-7 · Cited by 283
Fibrosis in chronic liver diseases: diagnosis and management
Pinzani, M., Rombouts, K., & Colagrande, S. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.008 · Cited by 267
P38 Mapk Mediates Fibrogenic Signal Through Smad3 Phosphorylation in Rat Myofibroblasts
Furukawa, F., Matsuzaki, K., Mori, S., Tahashi, Y., Yoshida, K., Sugano, Y., Yamagata, H., Matsushita, M., Seki, T., Inagaki, Y., et al. (2003) · Hepatology · doi:10.1002/hep.1840380414 · Cited by 265
Self-citationMcGuinness, P. H., Painter, D., Davies, S., & McCaughan, G. W. (2000) · Gut · doi:10.1136/gut.46.2.260 · Cited by 181
Mori, S., Matsuzaki, K., Yoshida, K., Furukawa, F., Tahashi, Y., Yamagata, H., Sekimoto, G., Seki, T., Matsui, H., Nishizawa, M., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207981 · Cited by 180
Self-citation森, 茂. (2004) · Medical Entomology and Zoology · Cited by 166
Yoshida, K., Matsuzaki, K., Mori, S., Tahashi, Y., Yamagata, H., Furukawa, F., Seki, T., Nishizawa, M., Fujisawa, J., & Okazaki, K. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62324-3 · Cited by 165
Self-citationYamagata, H., Matsuzaki, K., Mori, S., Yoshida, K., Tahashi, Y., Furukawa, F., Sekimoto, G., Watanabe, T., Uemura, Y., Sakaida, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.157.65.1 · Cited by 97
Self-citationOxidative stress and hepatitis C viral infection
Koike, K., & MIYOSHI, H. (2005) · Hepatology Research · doi:10.1016/j.hepres.2005.11.001 · Cited by 65
Matsuzaki, K., Date, M., Furukawa, F., Tahashi, Y., Matsushita, M., Sugano, Y., Yamashiki, N., Nakagawa, T., Seki, T., Nishizawa, M., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.9145 · Cited by 47
Self-citationSmad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis.
Matsuzaki, K. (2006) · PubMed · doi:10.14670/hh-21.645 · Cited by 45
Self-citationSugioka, Y., Watanabe, T., Inagaki, Y., Kushida, M., Niioka, M., Endo, H., Higashiyama, R., & Okazaki, I. (2004) · International Journal of Cancer · doi:10.1002/ijc.20095 · Cited by 36
Prevention and treatment of hepatocellular carcinoma
Omata, M., & Yoshida, H. (2004) · Liver Transplantation · doi:10.1002/lt.20046 · Cited by 20
Cited by
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Inflammation: Gearing the journey to cancer
KUNDU, J., & SURH, Y. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.03.002 · Cited by 803
TGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Targeting Macrophages in Cancer: From Bench to Bedside
Poh, A. R., & Ernst, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00049 · Cited by 501
Liu, J., Fan, L., Yu, H., Zhang, J., He, Y., Feng, D., Wang, F., Li, X., Liu, Q., Li, Y., et al. (2019) · Hepatology · doi:10.1002/hep.30607 · Cited by 449
Metadata
- Authors
- Matsuzaki, K., Murata, M., Yoshida, K., Sekimoto, G., Uemura, Y., Sakaida, N., Kaibori, M., Kamiyama, Y., Nishizawa, M., Fujisawa, J., Okazaki, K., & Seki, T.
- Venue
- Hepatology
- Published
- 2007-07
- Volume
- 46
- Issue
- 1
- Pages
- 48-57
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2034667224
- Cited by
- 292
- References
- 28
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.